Zoetis (NYSE:ZTS) Updates FY 2026 Earnings Guidance

Zoetis (NYSE:ZTS) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 6.150-6.250 for the period, compared to the consensus estimate of 6.870. The company issued revenue guidance of $9.1 billion-$9.3 billion, compared to the consensus revenue estimate of $9.8 billion.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. TD Cowen decreased their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. JPMorgan Chase & Co. decreased their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus lowered their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Finally, Barclays dropped their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $118.33.

Zoetis Trading Down 1.8%

ZTS opened at $74.64 on Thursday. The stock has a market capitalization of $31.29 billion, a P/E ratio of 12.38, a P/E/G ratio of 1.19 and a beta of 0.74. Zoetis has a 12 month low of $71.47 and a 12 month high of $160.48. The firm’s fifty day simple moving average is $76.78 and its 200 day simple moving average is $101.29. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts anticipate that Zoetis will post 6.87 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Activity

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock valued at $886,384 in the last quarter. Company insiders own 0.22% of the company’s stock.

Hedge Funds Weigh In On Zoetis

Several large investors have recently modified their holdings of ZTS. Prosperity Bancshares Inc acquired a new position in Zoetis in the 4th quarter valued at about $25,000. Intesa Sanpaolo Wealth Management acquired a new stake in Zoetis during the fourth quarter worth approximately $42,000. DV Equities LLC acquired a new stake in Zoetis during the fourth quarter worth approximately $77,000. Bellevue Group AG boosted its holdings in shares of Zoetis by 32.7% during the third quarter. Bellevue Group AG now owns 872 shares of the company’s stock worth $128,000 after acquiring an additional 215 shares during the period. Finally, Newbridge Financial Services Group Inc. boosted its holdings in shares of Zoetis by 23.7% during the third quarter. Newbridge Financial Services Group Inc. now owns 1,145 shares of the company’s stock worth $168,000 after acquiring an additional 219 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.